Global immunoprotein diagnostic testing market was pegged at $10.13 billion in 2019, and projected to reach $18.38 billion by 2027, growing at a CAGR of 6.6% from 2020 to 2027. This is attributed to increase in incidence of diseases due to rise in geriatric population, well-established healthcare systems, and increase in awareness among the population towards timely diagnosis of diseases.
The growth of the global immunoprotein diagnostic testing market is propelled by increase in incidence & prevalence of infectious and chronic diseases, rise in geriatric population, and growth in demand for early diagnostic services. In addition, technological advancements in immunodiagnostic instruments and introduction of novel automated systems are all set to augment the growth of the immunoprotein diagnostic testing market during the forecast period.
COVID-19 scenario:
- Due to lockdown across the globe, there is significant gap in supply and demand. Moreover, the supply chain has been disrupted.
- However, the demand for immunoprotein diagnostic testing is increasing as it could be used to diagnose cardiovascular and infectious diseases.
The global immunoprotein diagnostic testing market is segmented based on type, application, technology, and region. Based on technology, the immunoprotein diagnostic testing market is classified into radioimmunoassay, immunoturbidity assay, immunoprotein electrophoresis, enzyme-linked immunosorbent assay, and others. The enzyme-based immunosorbent assay segment held the largest share of 65.27% in 2019, owing to wide application of enzyme-based immunoassay.
Major market players
- Abbott Laboratories
- Bio-Rad Laboratories
- Abcam PLC
- Diasorin
- Danaher Corporation
- Ortho Clinical Diagnostics
- Enzo Life Sciences
- Siemens Healthcare
North America held the lion’s share
By region, the market across North America held the largest share in 2019, accounting for around two-fifths of the market, owing to increase in demand for quick diagnostic services to detect chronic diseases, ongoing trend of preventive healthcare, and rise in the number of drug abuse and allergy cases. However, the global immunoprotein diagnostic testing market across Asia-Pacific is projected to portray the highest CAGR of 7.7% during the forecast period, due to increase in the number of patients suffering from chronic diseases and improvement in healthcare facilities in the region.
Press-release: https://www.alliedmarketresearch.com/press-release/immunoprotein-diagnostic-testing-market.html
Web:https://www.alliedmarketresearch.com
Follow Us on LinkedIn:https://www.linkedin.com/company/allied-market-researc
0 Comments